Cefiderocol as Rescue Therapy for <i>Acinetobacter baumannii</i> and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients
Marco Falcone, Giusy Tiseo, Manuela Nicastro, Alessandro Leonildi, Alessandra Vecchione, Costanza Casella, Francesco Forfori, P Malacarne, Fabio Guarracino, Simona Barnini, Francesco Menichetti
Abstract
Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.
Topics & Concepts
Acinetobacter baumanniiMedicineIntensive care unitGramCarbapenemAcinetobacterMicrobiologyIntensive care medicineGram-negative bacterial infectionsAntibioticsPseudomonas aeruginosaBiologyBacteriaGeneticsAntibiotic Resistance in BacteriaVibrio bacteria research studiesInfections and bacterial resistance